Learn about common side effects associated with psoriasis treatments like corticosteroids, biologics, and JAK inhibitors, as well as how to manage them and balance benefits with risks.

Ruxolitinib cream received an expanded approval to treat patients as young as 2 years old with non-immunocompromised mild to ...

The FDA has expanded the indication of Incyte’s Opzelura (ruxolitinib) cream to include children aged two to 11 years with ...

Incyte INCY announced that the FDA has approved the label expansion of Opzelura (ruxolitinib) cream 1.5%. Opzelura, a topical ...

Janine Tugonon's name is once again making headlines, not for pageant-related updates, but for her candid revelations about ...

Nektar Therapeutics still needs to establish what differentiates rezpeg from other atopic dermatitis therapies, according to ...

FDA approves Incyte's Opzelura cream for children aged two and older with atopic dermatitis, expanding its use beyond teens ...